2018 ASCO Annual Meeting

$Gilberto Lopes, MD, MBA, Sylvester Comprehensive Cancer Center, University of Miami Health System, presenting LBA4, Pembrolizumab versus platinum-based chemotherapy as first-line therapy for advanced or metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ?1%: Phase 3 KEYNOTE-042 study, during \352#2\$

46 / 161

Gilberto Lopes, MD, MBA, Sylvester Comprehensive Cancer Center, University of Miami Health System, presenting LBA4, Pembrolizumab versus platinum-based chemotherapy as first-line therapy for advanced or metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ?1%: Phase 3 KEYNOTE-042 study, during \352#2\

Chicago, IL - 2018 ASCO Annual Meeting - Gilberto Lopes, MD, MBA, Sylvester Comprehensive Cancer Center, University of Miami Health System, presenting LBA4, Pembrolizumab versus platinum-based chemotherapy as first-line therapy for advanced or metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥1%: Phase 3 KEYNOTE-042 study," at the American Society of Clinical Oncology (ASCO) Annual Meeting here today, Sunday June 3, 2018. Approximately 40,000 physicians, researchers, and healthcare professionals from over 100 countries are attending the 54th Annual Meeting, which is being held at McCormick Place. The ASCO Annual Meeting highlights the latest findings in all major areas of oncology, from basic to clinical and epidemiological studies. Photo by © ASCO/Zach Boyden-Holmes 2018 Technical Questions: todd@medmeetingimages.com; ASCO Contact: photos@asco.org